160 Shares in Vertex Pharmaceuticals Incorporated $VRTX Bought by Caitong International Asset Management Co. Ltd

Caitong International Asset Management Co. Ltd bought a new position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) in the second quarter, HoldingsChannel reports. The fund bought 160 shares of the pharmaceutical company’s stock, valued at approximately $71,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Activest Wealth Management acquired a new position in shares of Vertex Pharmaceuticals during the first quarter worth $25,000. Clal Insurance Enterprises Holdings Ltd lifted its position in Vertex Pharmaceuticals by 450.0% in the first quarter. Clal Insurance Enterprises Holdings Ltd now owns 55 shares of the pharmaceutical company’s stock valued at $27,000 after acquiring an additional 45 shares during the last quarter. Flaharty Asset Management LLC purchased a new stake in Vertex Pharmaceuticals in the first quarter valued at $32,000. American National Bank & Trust lifted its position in Vertex Pharmaceuticals by 515.4% in the second quarter. American National Bank & Trust now owns 80 shares of the pharmaceutical company’s stock valued at $36,000 after acquiring an additional 67 shares during the last quarter. Finally, University of Texas Texas AM Investment Management Co. purchased a new stake in Vertex Pharmaceuticals in the first quarter valued at $46,000. Institutional investors and hedge funds own 90.96% of the company’s stock.

Insider Activity

In other news, Director Bruce I. Sachs purchased 5,000 shares of the company’s stock in a transaction dated Wednesday, August 6th. The shares were acquired at an average cost of $389.68 per share, for a total transaction of $1,948,400.00. Following the completion of the purchase, the director directly owned 45,000 shares in the company, valued at $17,535,600. The trade was a 12.50% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.20% of the stock is currently owned by company insiders.

Vertex Pharmaceuticals Stock Performance

NASDAQ VRTX opened at $421.39 on Friday. The firm has a market cap of $108.04 billion, a PE ratio of 30.12 and a beta of 0.43. Vertex Pharmaceuticals Incorporated has a one year low of $362.50 and a one year high of $519.88. The firm’s fifty day moving average is $398.96 and its two-hundred day moving average is $434.87.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its quarterly earnings data on Monday, August 4th. The pharmaceutical company reported $4.52 EPS for the quarter, beating analysts’ consensus estimates of $4.24 by $0.28. The company had revenue of $2.94 billion for the quarter, compared to analyst estimates of $2.90 billion. Vertex Pharmaceuticals had a net margin of 31.86% and a return on equity of 23.91%. Vertex Pharmaceuticals’s quarterly revenue was up 11.3% on a year-over-year basis. During the same period in the previous year, the business posted ($12.83) earnings per share. Vertex Pharmaceuticals has set its FY 2025 guidance at EPS. Research analysts predict that Vertex Pharmaceuticals Incorporated will post 15.63 earnings per share for the current year.

Analyst Upgrades and Downgrades

VRTX has been the subject of a number of research reports. UBS Group set a $553.00 price target on shares of Vertex Pharmaceuticals and gave the company a “buy” rating in a research report on Tuesday, August 5th. HC Wainwright reduced their price target on shares of Vertex Pharmaceuticals from $550.00 to $478.00 and set a “buy” rating for the company in a research report on Tuesday, August 5th. Guggenheim reduced their price target on shares of Vertex Pharmaceuticals from $558.00 to $546.00 and set a “buy” rating for the company in a research report on Wednesday, August 6th. Truist Financial set a $490.00 price target on shares of Vertex Pharmaceuticals and gave the company a “buy” rating in a research report on Tuesday, August 5th. Finally, Wall Street Zen cut shares of Vertex Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Friday, August 22nd. One analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and twelve have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $494.38.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.